FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2167482783> ?p ?o ?g. }

• W2167482783 endingPage "400" @default.
• W2167482783 startingPage "392" @default.
• W2167482783 abstract "EP3 receptor antagonists may provide a new approach to the treatment of atherothrombotic disease by blocking the ability of prostaglandin E2 (PGE2) to promote platelet function acting via EP3 receptors. DG-041 is an EP3 antagonist in the early stage of clinical development. Here, we quantitated effects on platelet function of DG-041 in-vitro and ex-vivo after administration to man when given alone and concomitantly with clopidogrel or clopidogrel and aspirin. With its unique mechanism of action, it was anticipated that DG-041 would potentiate inhibition of platelet function when given in combination with clopidogrel without materially increasing bleeding time. Initially, in-vitro studies were performed to determine inhibitory effects of DG-041 (3 µM) used alone or in combination with the P2Y12 antagonist cangrelor (1 µM), both without and with aspirin (100 µM). Platelet aggregation and P-selectin expression were measured in whole blood (n = 10) following stimulation with the thromboxane A2 (TXA2) mimetic U46619 (0.3 or 1 µM) in combination with either the EP3 agonist sulprostone (0.1 µM), or PGE2 (1 µM). DG-041 alone partially inhibited platelet function in-vitro, as did cangrelor. Addition of both DG-041 and cangrelor in combination provided significantly greater inhibition. An ex-vivo study was then performed using the same experimental approaches. This clinical study was a prospective, randomised, blinded (for DG-041/matching placebo), blocked, crossover study designed to compare the effects of DG-041, clopidogrel, or the combination of DG-041 with either clopidogrel or clopidogrel and aspirin. Healthy volunteers (n = 42) were randomly assigned to receive no background treatment, clopidogrel (300 mg loading dose plus 75 mg daily) or clopidogrel and aspirin (75 mg daily) for 10 days alongside DG-041 (200 mg twice daily) or placebo for 5 days, crossed over to placebo or DG-041 for the next 5 days. Platelet effects and bleeding time were measured at baseline, days 5 and 10. DG-041 partially inhibited platelet function ex-vivo, as did clopidogrel, while administration of both DG-041 and clopidogrel provided significantly greater inhibition. Administration of DG-041 alone did not increase bleeding time, and did not significantly affect the increased bleeding time seen with clopidogrel or clopidogrel with aspirin. Using these experimental approaches, the antiplatelet effects of DG-041 and a P2Y12 antagonist used alone and in combination can be determined both in-vitro and ex-vivo. Results show inhibitory effects of DG-041 on platelet function acting via EP3 receptor blockade, confirmed to be additional to those brought about by P2Y12 blockade. In both in-vitro and ex-vivo studies, aspirin neither promoted nor negated the effects of the other drugs." @default.
• W2167482783 created "2016-06-24" @default.
• W2167482783 creator A5003096433 @default.
• W2167482783 creator A5025529773 @default.
• W2167482783 creator A5044340641 @default.
• W2167482783 creator A5052708908 @default.
• W2167482783 creator A5068910626 @default.
• W2167482783 creator A5076488269 @default.
• W2167482783 creator A5089627879 @default.
• W2167482783 date "2012-08-06" @default.
• W2167482783 modified "2023-09-26" @default.
• W2167482783 title "Effects on platelet function of an EP3 receptor antagonist used alone and in combination with a P2Y₁₂antagonist both<i>in-vitro</i>and<i>ex-vivo</i>in human volunteers" @default.
• W2167482783 cites W179729331 @default.
• W2167482783 cites W1966433445 @default.
• W2167482783 cites W1969358114 @default.
• W2167482783 cites W1983442387 @default.
• W2167482783 cites W1987799591 @default.
• W2167482783 cites W2000339650 @default.
• W2167482783 cites W2000444831 @default.
• W2167482783 cites W2009822852 @default.
• W2167482783 cites W2013560303 @default.
• W2167482783 cites W2026653100 @default.
• W2167482783 cites W2039566216 @default.
• W2167482783 cites W2041684402 @default.
• W2167482783 cites W2069898552 @default.
• W2167482783 cites W2071260329 @default.
• W2167482783 cites W2103433677 @default.
• W2167482783 cites W2140895554 @default.
• W2167482783 cites W2145772474 @default.
• W2167482783 cites W2151528138 @default.
• W2167482783 doi "https://doi.org/10.3109/09537104.2012.704648" @default.
• W2167482783 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22866894" @default.
• W2167482783 hasPublicationYear "2012" @default.
• W2167482783 type Work @default.
• W2167482783 sameAs 2167482783 @default.
• W2167482783 citedByCount "27" @default.
• W2167482783 countsByYear W21674827832012 @default.
• W2167482783 countsByYear W21674827832013 @default.
• W2167482783 countsByYear W21674827832014 @default.
• W2167482783 countsByYear W21674827832015 @default.
• W2167482783 countsByYear W21674827832016 @default.
• W2167482783 countsByYear W21674827832017 @default.
• W2167482783 countsByYear W21674827832018 @default.
• W2167482783 countsByYear W21674827832019 @default.
• W2167482783 countsByYear W21674827832020 @default.
• W2167482783 countsByYear W21674827832021 @default.
• W2167482783 countsByYear W21674827832022 @default.
• W2167482783 crossrefType "journal-article" @default.
• W2167482783 hasAuthorship W2167482783A5003096433 @default.
• W2167482783 hasAuthorship W2167482783A5025529773 @default.
• W2167482783 hasAuthorship W2167482783A5044340641 @default.
• W2167482783 hasAuthorship W2167482783A5052708908 @default.
• W2167482783 hasAuthorship W2167482783A5068910626 @default.
• W2167482783 hasAuthorship W2167482783A5076488269 @default.
• W2167482783 hasAuthorship W2167482783A5089627879 @default.
• W2167482783 hasConcept C126322002 @default.
• W2167482783 hasConcept C185592680 @default.
• W2167482783 hasConcept C202751555 @default.
• W2167482783 hasConcept C26291073 @default.
• W2167482783 hasConcept C2776708134 @default.
• W2167482783 hasConcept C2777628954 @default.
• W2167482783 hasConcept C2777849778 @default.
• W2167482783 hasConcept C2781024287 @default.
• W2167482783 hasConcept C2909112448 @default.
• W2167482783 hasConcept C49059817 @default.
• W2167482783 hasConcept C55493867 @default.
• W2167482783 hasConcept C71924100 @default.
• W2167482783 hasConcept C89560881 @default.
• W2167482783 hasConcept C98274493 @default.
• W2167482783 hasConceptScore W2167482783C126322002 @default.
• W2167482783 hasConceptScore W2167482783C185592680 @default.
• W2167482783 hasConceptScore W2167482783C202751555 @default.
• W2167482783 hasConceptScore W2167482783C26291073 @default.
• W2167482783 hasConceptScore W2167482783C2776708134 @default.
• W2167482783 hasConceptScore W2167482783C2777628954 @default.
• W2167482783 hasConceptScore W2167482783C2777849778 @default.
• W2167482783 hasConceptScore W2167482783C2781024287 @default.
• W2167482783 hasConceptScore W2167482783C2909112448 @default.
• W2167482783 hasConceptScore W2167482783C49059817 @default.
• W2167482783 hasConceptScore W2167482783C55493867 @default.
• W2167482783 hasConceptScore W2167482783C71924100 @default.
• W2167482783 hasConceptScore W2167482783C89560881 @default.
• W2167482783 hasConceptScore W2167482783C98274493 @default.
• W2167482783 hasIssue "5" @default.
• W2167482783 hasLocation W21674827831 @default.
• W2167482783 hasLocation W21674827832 @default.
• W2167482783 hasOpenAccess W2167482783 @default.
• W2167482783 hasPrimaryLocation W21674827831 @default.
• W2167482783 hasRelatedWork W179729331 @default.
• W2167482783 hasRelatedWork W186366351 @default.
• W2167482783 hasRelatedWork W1980074266 @default.
• W2167482783 hasRelatedWork W1984721873 @default.
• W2167482783 hasRelatedWork W2009822852 @default.
• W2167482783 hasRelatedWork W2167482783 @default.
• W2167482783 hasRelatedWork W2189601282 @default.
• W2167482783 hasRelatedWork W2574602345 @default.
• W2167482783 hasRelatedWork W2763802711 @default.
• W2167482783 hasRelatedWork W2767233201 @default.

• next